Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Beveridge

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of the National Cancer Institute|July 3, 1991
High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancerM J Kennedy, R A Beveridge, S D Rowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancerM J Kennedy, G B Vogelsang, R A Beveridge, et al.
Lancet (London, England)|April 18, 2000
High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda studyR B Weiss, R M Rifkin, F M Stewart, et al.
Cancer|June 15, 1980
Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunityA M Baskies, P B Chretien, J F Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III diseaseD W Chan, R A Beveridge, H Muss, et al.
Clinical Chemistry|October 1, 1988
Monitoring breast cancer with CA 549D W Chan, R A Beveridge, D J Bruzek, et al.
Advances in Experimental Medicine and Biology|January 1, 1996
A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrowW R Vogler, W E Berdel, R B Geller, et al.
Journal of the National Cancer Institute|April 4, 1990
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancerM D Abeloff, R A Beveridge, R C Donehower, et al.
Clinical Therapeutics|May 1, 1993
Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patientsJ A Miller, T Butler, R A Beveridge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1988
A new biomarker in monitoring breast cancer: CA 549R A Beveridge, D W Chan, D Bruzek, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of the National Cancer Institute|July 3, 1991
High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancerM J Kennedy, R A Beveridge, S D Rowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancerM J Kennedy, G B Vogelsang, R A Beveridge, et al.
Lancet (London, England)|April 18, 2000
High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda studyR B Weiss, R M Rifkin, F M Stewart, et al.
Cancer|June 15, 1980
Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunityA M Baskies, P B Chretien, J F Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III diseaseD W Chan, R A Beveridge, H Muss, et al.
Clinical Chemistry|October 1, 1988
Monitoring breast cancer with CA 549D W Chan, R A Beveridge, D J Bruzek, et al.
Advances in Experimental Medicine and Biology|January 1, 1996
A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrowW R Vogler, W E Berdel, R B Geller, et al.
Journal of the National Cancer Institute|April 4, 1990
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancerM D Abeloff, R A Beveridge, R C Donehower, et al.
Clinical Therapeutics|May 1, 1993
Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patientsJ A Miller, T Butler, R A Beveridge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1988
A new biomarker in monitoring breast cancer: CA 549R A Beveridge, D W Chan, D Bruzek, et al.
Pageof 3